Therapeutic strategy of third-generation autologous chondrocyte implantation for osteoarthritis by Kuroda, Tomoya et al.
Upsala Journal of Medical Sciences. 2011; 116: 107–114
ORIGINAL ARTICLE
Therapeutic strategy of third-generation autologous chondrocyte
implantation for osteoarthritis
TOMOYA KURODA
1,2, TOMOYUKI MATSUMOTO
1,2, YUTAKA MIFUNE
1,2,
TOMOAKI FUKUI
1,2, SEIJI KUBO
1, TAKEHIKO MATSUSHITA
1, TAKAYUKI ASAHARA
2,3,
MASAHIRO KUROSAKA
1 & RYOSUKE KURODA
1
1Kobe University Graduate School of Medicine/Department of Orthopaedic Surgery, Kobe, Japan,
2Stem Cell
Translational Research, Kobe Institute of Biomedical Research and Innovation, Kobe, Japan, and
3Department of
Regenerative Medicine Science, Tokai University School of Medicine, Tokai, Japan
Abstract
Background. Autologous chondrocyte implantation (ACI) is considered a promising choice for the treatment of cartilage
defects. However, the application of ACI toosteoarthritic patients is, in general, contraindicated. The purposeof this study is to
evaluate the efﬁciency of three-dimensionallystructured ACI (3D-ACI; CaReS) in a rat model of knee osteoarthritis (OA).
Methods. OA-like degenerative changes in the articular cartilage were created by transecting the anterior cruciate ligament
(ACLT) in athymic nude rats. Two weeks later, CaReS was transplanted at the cartilage injury sites created by micro-drilling in
the patella groove (Chondrocyte-implanted (CI) group: CaReS collagen with human chondrocytes; Collagen group: CaReS
collagen without cells; and Sham group: sham operation; n = 15/group).
Results. Reverse Transcription Polymerase Chain Reaction (RT-PCR) analysis demonstrated the expression of human-
speciﬁc type 2 collagen and Sry-type high-mobility-group box 9 (SOX9) in the CI group—not in the other groups—throughout
thestudyperiod.Doubleimmunohistochemistryforhuman-speciﬁctype2collagenandhumanleukocyteantigen-abacavir(HLA-
ABC)atweek4showedpositivestainingintheCIgrouponly.Macroscopicassessmentshowedbetterrepairatthecartilagedefect
sitesintheCIgroup,comparedtotheothergroups.Histologicalassessmentwithtoluidinebluestainingshowedthatthethicknessof
thearticularcartilageandsemi-quantitativehistologicalscoreswerehigherintheCIgroupthanintheothergroupsuptoweek20.
Conclusions. We demonstrate, for the ﬁrst time, that 3D-ACI is effective in repairing cartilage defects in a rat model of
ACLT-induced OA.
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Introduction
Knee osteoarthritis (OA), a clinical syndrome with
low-grade inﬂammation caused by abnormal wear of
the articular cartilage, is associated with pain, destruc-
tion of joints, and/or a decrease in the synovial ﬂuid
that lubricates the joints. It is estimated that the
number of patients with knee OA is more than 21 mil-
lion in the US, and symptomatic OA of the knee
occurs in 6% of adults aged 30 or older and 13%
of people aged 60 or over (1). However, it is also well
known that because of the limited capacity of the
cartilage for repair, abnormal wear of the articular
cartilage is a major clinical problem when the cartilage
becomes damaged (2).
Recently, various therapeutic strategies includ-
ing bone-marrow stimulation and transplantation of
osteochondral autografts or allografts have been devel-
oped to restore articular cartilage so as to achieve a
permanent repair (3). Among them, autologous chon-
drocyte implantation (ACI) is a promising choice for
cartilage repair. The classical ACI (ﬁrst generation)
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the US Food and Drug Administration in 1997 (5).
This ﬁrst-generation ACI provided signiﬁcant and
long-term beneﬁts for patients in terms of diminished
pain and improved function (6). In order to overcome
the hypertrophy or ossiﬁcation of the patched perios-
teum and the complex operative technique associated
with ﬁrst-generation ACI, a second-generation ACI
was developed, in which bioengineered bilayer colla-
gen or synthetic membranes were used in order to
avoid spill-over and asymmetric distribution of chon-
drocytes following implantation. In some products, a
periosteal ﬂap is not needed.
Recently, further technological advances have led
to a third-generation ACI, where chondrocytes are
embedded into three-dimensionally constructed scaf-
folds (i.e. 3D environment) for cell growth. These
‘all-in-one’ grafts do not need a periosteal cover or
ﬁxing stitches and can be trimmed to exactly ﬁt into
the cartilage defect with ﬁbrin glue (7). Indeed, sev-
eral clinical studies of 3D-ACI for cartilage injury
have been reported (2,4,8–10). Despite the advan-
tages of this new technique in surgical simplicity,
shorter operating time, and the possibility of perform-
ing the surgery via a mini-arthrotomy or arthroscopy,
the product has contraindication for use in patients
suffering from OA. However, there are several studies
in which favorable clinical outcomes have been
reported (7,11). Therefore, the purpose of this study
is to evaluate the efﬁciency of 3D-ACI using a rat
model of knee osteoarthritis produced by transection
of the anterior cruciate ligament (ACL).
Materials and methods
OA animal model
The institutional animal care and committees of
RIKEN Center for Developmental Biology approved
all animal procedures. Female athymic nude rats
(F344/N Jcl rnu/rnu, Japan clea) aged 8–10 weeks,
weighing an average of 200 g, underwent ACL tran-
section (ACLT) as previously reported (12). Ani-
mals were brieﬂya n e s t h e t i z e db ya ni n t r a p e r i t o n e a l
injection of ketamine hydrochloride (60 mg/kg) and
with ether. After shaving of the knee joint, a para-
patellar incision was made, followed by lateral dis-
placement of the patella, thereby enabling access to
the joint space. The ACL was then easily visible and
surgically excised. The increase in anterior displace-
ment of the tibia in relation to the femur was used to
ensure that the ligament was transected. The surgical
incision was then closed. At the end of the 2-week
post-surgical period, in order to conﬁrm the
progression to OA, the knee joints were opened
in a parapatellar approach, and the entire knee was
examined macroscopically and photographed. Then
the distal femurs were removed and histologically
assessed as described later.
Preparation of chondrocytes and collagen matrix
In this study, to meet the demand supposing a
clinical use, we used human chondrocytes. Human
chondrocytes isolated from a healthy volunteer
(28 years old, African-American) were purchased
from Lonza (Basel, Switzerland). To expand these
cells, 1  10
5 cells were plated in 6-well dishes with
standard medium (alpha-MEM; GibcoBRL, Invi-
trogen Japan K.K., Tokyo, Japan) containing
10% fetal bovine serum (Vitromex, San Antonio,
TX, USA), 2 mM L-glutamine (GibcoBRL), 100
units/mL penicillin (GibcoBRL), and 100 mg/mL
streptomycin (GibcoBRL) and incubated at 37C
with 5% CO2 in ambient air. The medium was
replaced every 3–4 days. After culture for 14 days,
the cells were harvested with 0.25% trypsin/1mM
EDTA solution (GibcoBRL) and counted. CaReS
(Arthro Kinetics, Krems am de Donau, Austria) is a
3D mechanically stable transplantation system
b a s e do np a t i e n t - s p e c i ﬁc autologous cartilage cells.
These counted cells were expanded in vitro accord-
ing to CaReS manufacturer’s protocol. In brief, they
were expanded with standard medium (see above)
and subsequently 2  10
7 cells were mixed with
50 mL collagen MS solution, a gel neutralization
solution (Arthro Kinetics, Krems am de Donau,
Austria). An appropriate volume of the above solu-
tion was pipetted into microtiter plates and incu-
bated for 20 minutes. Culture was performed at
37C, 5% CO2, and 95% Relative Humidity (RH)
for 10–14 days. Culture medium was removed from
the gel every 3–4 days and replaced by fresh and
preheated (37C) medium. Preparation of collagen
matrix without cells was conducted in the same
manner as those with cells, except that no cells
were seeded.
Cell implantation and study groups
A parapatellar incision was made, and the knee joint
was exposed via lateral dislocation of the patella. To
make an appropriate space to mount the chondrocyte-
loaded collagen implant in the trochlear groove of
each femur, a 1.5-mm diameter micro-drill was used.
Animals in the chondrocyte-implanted (CI) group
were treated with several mm of the chondrocyte-
loaded collagen gel (normal articular cartilage
thickness is 0.072 ± 0.013 mm (13)) and ﬁxed with
108 T. Kuroda et al.ﬁbrin glue (Kaketsuken, Kumamoto, Japan) to keep
the implant stable. Animals in the collagen group were
treated with ﬁbrin glue-ﬁxed collagen implants with-
out cells. Animals in the sham group were treated with
ﬁbrin glue only (n = 15 each). After surgery, the rats
were allowed to move freely within their cages. No
animal was observed to have an abnormal gait or
impaired locomotion.
RT-PCR analysis of RNA isolated from
transplantationsites
To examine human cell-derived chondrogenesis,
mRNA expression for chondrogenic markers (human-
speciﬁctype2collagen(COL2)andSOX9)wasassessed
byRT-PCRanalysis.Atweek4,totalRNAwasobtained
from the transplantation sites using Tri-zol (Life
Technologies, Gaithersburg, MD, USA) according to
themanufacturer’sinstructions.First-strandcDNAwas
synthesizedusingtheRNALAPCRKitVer1.1(Takara
Bio. Inc., Otsu, Japan), ampliﬁed by Taq DNA poly-
merase(Advantage-GCcDNA PCRKit,Clontechand
AmpliTaq Gold DNA polymerase, Applied Biosys-
tems). PCR was performed using a PCR thermocycler
(MJ research PTC-225). And hCOL2, hSOX9, and
rGAPDH were ampliﬁed by Taq DNA polymerase
(Advantage-GC cDNA PCR Kit, Clontech) at the fol-
lowing conditions: 35 cycles of 30-second initial dena-
turation at 94C, annealing at 56C for 1 minute, and
30 seconds of extension at 72C according to the man-
ufacturer’s instructions. Subsequently, PCR products
were visualized in 1.5% ethidium bromide stained aga-
rose gels. Human chondrocytes (Lonza) were used for
positivecontrolforhuman-speciﬁcchondrocyte-related
genes.
Primers
To avoid interspecies cross-reactivity of the primer
pairs between human and rat genes, we designed the
following human-speciﬁc primers using Oligo soft-
ware (Takara Bio. Inc.). None of the primer pairs
showed any cross-reactivity to rat genes (data not
shown).
. hCOL2 primer sequence: sense AAG CAA GTA
GCG CCA ATC T; antisense GGA AGT AGG
GTG CCA TAA CAC
. hSOX9 primer sequence: sense ATG TTT GGC
CTG AAG CAG AGA; antisense GGC GGT
ACA GGT CGA GCA TAT A
. rGAPDH primer sequence: sense CTG ATG
CCC CCA TGT TCG TC; antisense CAC
CCT GTT GCT GTA GCC AAA TTC G
Tissue harvesting
Ratswereeuthanizedwithanoverdoseofketamineand
xylazine. Bilateral femurs were harvested and quickly
embedded in optimal cutting temperature (OCT)
compound (Miles Scientiﬁc, Elkhardt, IN, USA),
snap-frozen in liquid nitrogen, and stored at 80C
for histochemical and immunohistochemical staining
as described previously (14). Rat femurs in OCT
blocks were sectioned, and 6-mm serial sections were
mounted on silane-coated glass slides and air dried for
1h o u rb e f o r eb e i n gﬁxed with 4.0% paraformaldehyde
at 4C for 5 minutes and stained immediately.
Immunohistochemical staining
To detect the chondral restoration by transplanted
human cells in the rat tissue at week 4, immunohis-
tochemistry was performed with the following
human-speciﬁc antibodies; human leukocyte antigen
(HLA)-ABC (Becton-Dickinson (BD) Pharmingen,
Franklin Lakes, NJ, USA) to detect various lineages of
human cells and hCOL2 (BD Pharmingen) to
detect human cell-derived chondrocytes. Staining
speciﬁcity for human cells without cross-reaction to
rat cells was conﬁrmed by histochemical staining for
HLA-ABC and hCOL2 using rat and human chon-
drocytes (Lonza) (data not shown). The secondary
antibodies for each immunostaining were as follows:
Alexa Fluor 594-conjugated goat anti-mouse IgG1
(Molecular Probes, Invitrogen Japan K.K., Tokyo,
Japan) for HLA-ABC staining and Alexa Fluor
488-conjugated goat anti-mouse IgG2a (Molecular
Probes) for hCOL2. DAPI solution was applied for
5 minutes for nuclear staining. Double immunohis-
tochemistry with HLA-ABC and hCOL2 was per-
formed to detect human chondrocytes in the articular
cartilage.
Macroscopic and histological assessment of cartilage
regeneration
To conﬁrm the sequential recovery from OA-like
arthritis, we performed macroscopic and histological
evaluation from 0 to 20 weeks after operation. The
rats were euthanized at 4, 8, and 20 weeks after the
operation. The entire knee was dissected, examined
macroscopically, and photographed.
The distal parts of the femur were then ﬁxed as
described above. Each specimen was sectioned
(5 mm thick) sagittally and perpendicularly to the
defect. The sections were stained with toluidine
blue. These sections were obtained from the center
of the defect, and as many as ten such sections were
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animal were examined and scored independently by
three blinded observers. We evaluated chondral
repair semi-quantitatively using a grading and scor-
ing system, which is a modiﬁcation of that described
by Prizker et al. (15). The scale is composed of six
histological gradings (0: surface intact, cartilage
i n t a c t ;1 :s u r f a c ei n t a c t ;2 :s u r f a c ed i s c o n t i n u i t y ;3 :
vertical ﬁs s u r e s ;4 :e r o s i o n ;5 :d e n u d a t i o n ;6 :d e f o r -
mation) and four histological stages (0: no OA activ-
ity; 1: <10% involvement (surface, area, volume);
2: 10%–25%; 3: 25%–50%; 4: >50%) assigning a
total score (score = grade  stage) ranging from
1 point (normal articular cartilage) to 24 points
(no repair).
Statistical analysis
The results were statistically analyzed using a soft-
ware package (Microsoft Ofﬁce Excel, Microsoft
Corporation, Washington, USA). All values were
expressed as means ± SE. Multiple comparisons
among groups were made using a one-way ana-
lysis of variance (ANOVA). Post-hoc analysis was
performed by Fisher’s PLSD test. A probability
value < 0.05 was considered to denote statistical
signiﬁcance.
Results
Conﬁrmation of ACLT model of rat osteoarthritis
At 2 weeks after the ACLT operation, irregular artic-
ular surface and osteophyte formation around the
margin of the bilateral femoral condyle and the patella
groove were conﬁrmed (Figure 1A). Toluidine blue
staining showed gradual reduction of the thickness of
the articular cartilage layer in the patella groove
(Figure 1B).
Chondrogenesis by transplanted human cells
To histologically validate the phenomenon of human
cell-derived chondrogenesis at the repair sites, HLA-
ABC staining for various lineages of human cells and
hCOL2 for human cell-derived chondrocytes was
performed using tissue samples obtained at 4 weeks
after implantation. Transplanted human cells were
detected as HLA-ABC-positive cells. Differentiated
human chondrocytes derived from the transplanted
cells were detected as hCOL2-positive cells at the
chondral repair site in the CI group, while hCOL2-
positive cells were not identiﬁed in the other groups
(Figure 2A). The number of double-stained cells
was higher in the CI group compared to the other
groups (CI group 820 ± 52.3/mm
2; Collagen group
A Day 0 Day 7 Day 14
B
Figure 1. Rat osteoarthritis (OA) model with anterior cruciate ligament transection. A: Macroscopic appearance of the anterior cruciate
ligament transection (ACLT) model of rat OA. At 2 weeks post-surgery, the joints have obvious articular surface damage and osteophyte
formationaround the margin of the medial femoralcondyles and the patellagroove. B: Toluidine blue staining showing the thicknessof gradual
degeneration of the patellar groove (Original magniﬁcation 20).
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2; Sham group0.0 ± 0.0/mm
2, respec-
tively (P < 0.01 for CI group versus the other groups)).
RT-PCR analysis of tissue RNA, isolated from the
transplantation sites, for human-speciﬁc chondro-
genic markers (hCOL2 and hSOX9) revealed that
expression of hCOL2 and hSOX9 was detected in the
CI group but not in the other groups (Figure 2B).
Macroscopic and histological recovery of regenerated
cartilage
Macroscopic assessment showed better recovery as
judged by smooth surface of articular cartilage in the
CI group when compared to the other groups at week
4 and 8 (Figure 3A). Histological assessment with
toluidine blue staining (Figure 3B) showed that the
thickness of the articular cartilage was signiﬁcantly
higher in the CI group than in the other groups at
week 4 (CI group 15.3 ± 4.1 mm; Collagen group
6.0 ± 1.0 mm; Sham group 5.0 ± 2.0 mm, respec-
tively; P < 0.05 for CI group versus the other groups).
The differences between the CI group and the other
groups also attained statistical signiﬁcance at week
8 (CI group 27.5 ± 3.6 mm; Collagen group 9.7 ±
2.5 mm; Sham group 8.3 ± 1.5 mm, respectively;
P < 0.05 for CI group versus the other groups). Semi-
quantitative histological scorings at week 4 and 8 were
better in the CI group than in the other groups (week
4: CI group 5.2 ± 1.1, Collagen group 9.0 ± 2.1, Sham
group 15.6 ± 1.1; week 8: CI group 1 ± 0, Collagen
group 7.8 ± 1.6, Sham group 14 ± 2.2, respectively;
P < 0.05 for CI group versus the other groups).
However, at week 20, the surfaces of the articular
cartilage did not differ among the three groups
(Figure 3A). Histological assessment with toluidine
blue staining at week 20 nevertheless showed that the
articular cartilage was thicker in the CI group than in
the other groups, although the decreasing trend of the
thickness was maintained (CI group 13.0 ± 3.6 mm;
Collagen group 2.6 ± 1.2 mm; Sham group 3.0 ±
1.0 mm, respectively; P < 0.05 for CI versus the other
groups) (Figure 3B). In line with this, the histological
score at week 20 was still better in the CI group than
in the other groups (CI group 8 ± 2.8; Collagen group
12 ± 2.8; Sham group 22 ± 2.8, respectively;
P < 0.05 for CI versus the other groups).
Discussion
OA is characterized by the progressive loss of articular
cartilage that leads to chronic pain and functional
restrictions in affected joints. In the past decades,
various surgical procedures including microfracture
(16,17), autologous grafting procedures (18,19) and
mosaicplasty (20,21) have been developed for the
treatment of cartilage defects. However, there are
1
CI Collagen Sham
hCOL2
hSOX9
hGAPDH
23 45
A
B
Figure 2. Cartilage regeneration by transplanted human cells. A: Representative double immunostaining for hCOL2 (green) and HLA-
ABC (red) using tissue sample of the regenerated articular cartilage at week 4 (original magniﬁcation 200).Human-derived chondrocytes
were identiﬁed as double-stained cells with hCOL2 and HLA-ABC at the chondral repair site in the CI group (yellow area), but not in the other
groups. B: RT-PCR analysis for human-speciﬁc chondrogenic markers of tissue RNA isolated from the chondral repair sites. Expression of
hCOL2and hSOX9wasdetectedin the CIgroup,butnot in theother groups.1:CIgroup.2:Collagen group.3:Shamgroup.4:Chondrocytes
(positive control). 5: No RNA (negative control).
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Figure 3. Macroscopic and histological evaluation at weeks 4, 8, and 20. A: Macroscopic assessment showing a better recovery as judged by a
relatively smooth surface of the articular cartilage in the CI group compared to the other groups at weeks 4 and 8. In contrast, there was no
apparent difference in the thickness of the articular cartilage between the three groups at week 20. Arrows indicate the defect area. B:
Histological assessment with toluidine blue staining showing that the thickness of the articular cartilage was higher in the CI group than in the
other groups at weeks 4, 8, and 20. However, at week 20, the thickness of the articular cartilage was decreasing in all groups. Arrow heads
indicate the thickness of the articular cartilage.
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articular surface. In recent years, chondrocyte
implantation techniques, namely ACI, have emerged
as a potential therapeutic option. Some studies also
suggest a certain durability of the ACI, even in long-
term follow-up studies, possibly because of its ability
to produce hyaline-like cartilage and better integra-
tion with the adjacent articular surface (22,23).
Until now, the efﬁcacy of ACI in patients suffering
from OA has remained unclear. Several researchers
reported the application of ACI to patients older than
45 years or who had failed prior treatments for artic-
ular cartilage defects of the knee (24,25). However, in
these studies, OA-like changes of the articular carti-
lage was part of the excluding criteria. In the present
study, we used collagen matrix, CaReS, as a third-
generation autologous chondrocyte implant. The
CaReS is a 3D collagen type 1 gel, and the thickness
of the transplants can be adjusted to the thickness of
the cartilage in each patient. Some clinical reports
using the CaReS are encouraging, even in patella-
femoral defects (26). However, there are no reports
showing the usefulness of CaReS for cartilage repair
in patients suffering from OA.
In this study, we used human chondrocytes in
athymic nude rats. Using this xenotransplantation
animal model, to conﬁrm cartilage regeneration
and maturation of human chondrocytes, molecular
and immunohistological assessments using human-
speciﬁc markers were conducted. RT-PCR and
immunohistochemistry demonstrated survival of
implanted chondrocytes at the defect site of the rat
knee. This scientiﬁc approach provides us with useful
information demonstrating the mechanistic effect of
the third-generation ACI for OA. As the next step, we
are planning to conduct a clinical trial to investigate
the proof of concept of CaReS for use in focal OA
patients. In addition, whereas a comparison of the
CaReS technique with standard ACI is beyond the
scope of the current study, comparative experiments
to examine the effects of different ACI techniques in
OA animal models are warranted. In the present
study, we used human chondrocytes isolated from a
relatively young volunteer. Although we intend to use
this system for relatively young OA patients with focal
OA regions, implantation of chondrocytes from older
patients should also be investigated for the conﬁrma-
tion of the efﬁcacy of the system also in that group of
OA patients.
There was increased thickness of the articular car-
tilage and little deformity around the defect site when
comparing the CI group with the other groups. This
may be taken to indicate that the CI contributes to the
stability of the cartilage. Up to 8 weeks, the thickness
of articular cartilage at the defect sites in the CI group
improved even when OA was getting worse due to the
instability of the knee joint following ACL resection.
However, at week 20, there was no increase of the
thickness of the articular cartilage in the CI group. In
the clinical setting, ligamentous instability is usually
included in the excluding criteria of the study design.
Hollander et al. described that OA did not inhibit
tissue regeneration and might even have enhanced it,
suggesting that degenerating tissues are primed for
repair and require only the appropriate cellular cues
and environment for proper regeneration of healthy
tissue (27). Cartilage degradation in OA is considered
to involve a delicate imbalance between anabolic and
catabolic processes (28). Injured joints without OA
may lack the endogenous anabolic pathways. There-
fore, they must rely entirely on the introduced cells to
produce a repair. In other words, joints with OA may
repair relatively more easily than without OA.
There are some limitations in this study, such as for
instance that we used bovine serum to prepare the
graft. The use of human serum should preferably be
investigated for clinical settings. In addition, we used a
1.5-mm diameter micro-drill in order to stabilize the
implant and ensure that the medullary canal space was
not reached. However, there might be a possibility that
there might be an effect of chondroprogenitor cells on
the articular cartilage. Hayes et al. described that the
unique distribution of sulfation motifs within the
microenvironment of superﬁcial zone chondrocytes
seems to designate early stages of stem/progenitor
cell differentiation and is consistent with the fact
that these molecules play a functional role in regulating
aspects of chondrogenesis (29).
InthepresentstudyusingaratOAmodel,weshowed
the therapeutic potential of third-generation ACI for
treating cartilage defects of knee OA. We believe our
ﬁndings provide new insights into the treatment of OA
andbroadentheapplicationofthird-generationACIfor
knee OA as a new surgical modality.
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